Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
30.96
-0.99
(-3.10%)
As of 11:29:57 AM GMT+8. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jun Xiong | Executive Chairman | 7.12M | -- | 1974 |
| Mr. Cong Li | Co-CEO & Executive Director | 4.22M | -- | 1964 |
| Dr. Jianjun Zou M.D., Ph.D. | GM, CEO & Executive Director | 5.86M | -- | 1971 |
| Dr. Ning Li M.D., Ph.D. | Executive Vice-Chairman of the Board | 7.3M | -- | 1961 |
| Mr. Baohong Xu | Financial Director | -- | -- | 1979 |
| Mr. Zhuobing Zhang | Deputy GM & Executive Director | 6.74M | -- | 1967 |
| Dr. Sheng Yao Ph.D. | Senior VP & Executive Director | 4.64M | -- | 1975 |
| Dr. Gang Wang | Deputy GM, Chief Quality Officer, Senior VP of Industry Affairs & Executive Director | 1.14M | -- | 1957 |
| Dr. Xin Li | Senior VP of Government Affairs & Executive Director | -- | -- | 1979 |
| Ms. Lu Yuan | Assistant to GM & Chief of Internal Audit Department | -- | -- | 1982 |
Shanghai Junshi Biosciences Co., Ltd.
Building 7, No. 6
Floor 16 Lane 100, Pingjiaqiao Road Pudong New District
Shanghai, 200126
China
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2,568
Description
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Corporate Governance
Shanghai Junshi Biosciences Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
2171.HK CARsgen Therapeutics Holdings Limited
16.520
-1.43%
2696.HK Shanghai Henlius Biotech, Inc.
27.300
-3.36%
9939.HK Kintor Pharmaceutical Limited
1.120
-6.67%
AVBP ArriVent BioPharma, Inc.
23.70
-2.79%
1548.HK GENSCRIPT BIO
12.660
-4.52%
ITOS iTeos Therapeutics, Inc.
7.00
-0.99%
6160.HK BeiGene, Ltd.
167.500
+3.65%
1801.HK INNOVENT BIO
41.300
-4.40%
ONC BeiGene, Ltd.
278.38
+7.48%
LEGN Legend Biotech Corporation
36.72
+0.52%